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Objective. To determine the significance of high serum ferritin observed in Indigenous Australian patients on maintenance
haemodialysis in the Northern Territory, we assessed the relationship between ferritin and transferrin saturation (TSAT) as
measures of iron status and ferritin and C-reactive protein (CRP) as markers of inflammation. Methods. We performed a
retrospective cohort analysis of data from adult patients (≥18 years) on maintenance haemodialysis (>3 months) from 2004 to 2011.
Results. There were 1568 patients. The mean age was 53.9 (11.9) years. 1244 (79.3%) were Indigenous. 44.2% (𝑛 = 693) were male.
Indigenous patients were younger (mean age [52.3 (11.1) versus 57.4 (15.2), 𝑝 < 0.001]) and had higher CRP [14.7mg/l (7–35) versus
5.9mg/l (1.9–17.5), 𝑝 < 0.001], higher median serum ferritin [1069 𝜇g/l (668–1522) versus 794.9 𝜇g/l (558.5–1252.0), 𝑝 < 0.001],
but similar transferrin saturation [26% (19–37) versus 28% (20–38), 𝑝 = 0.516]. We observed a small positive correlation between
ferritin and TSAT (𝑟2 = 0.11, 𝑝 < 0.001), no correlation between ferritin and CRP (𝑟2 = 0.001, 𝑝 < 0.001), and positive association
between high serum ferritin and TSAT (𝑝 < 0.001), Indigenous ethnicity (𝑝 < 0.001), urea reduction ratio (𝑝 = 0.001), and gender
(𝑝 < 0.001) after adjustment inmixed regression analysis.Conclusion. Serum ferritin and TSATmay inadequately reflect iron status
in this population. The high ferritin was poorly explained by inflammation.
1. Introduction
The effective treatment of anaemia in patients on main-
tenance haemodialysis (MHD) includes identification and
correction of iron deficiency [1], use of erythropoiesis stim-
ulating agents (ESA) as necessary, and achieving dialysis
adequacy. Interpretation of iron status from most guidelines
on anaemiamanagement in people onMHDhas beenmainly
based on transferrin saturation [the ratio of serum iron to the
total iron binding capacity (TIBC) as a percentage, TSAT]
and serum ferritin. Other measures of iron status have also
been examined and include percentage hypochromic red
cells (PHRC), reticulocyte haemoglobin content, and soluble
transferrin receptor [2–4]. The accurate determination of
iron status is critical in patients dependent on maintenance
haemodialysis in order to avoid overtreatment resulting in
iron overload and minimising continuing anaemia from
undertreatment of iron deficiency.
The combination of serum ferritin levels and TSAT are
commonly used worldwide in Renal Anaemia Management
guidelines [2, 5]. Low TSAT and low ferritin are indicative of
iron deficiency. However, recent published evidence suggests
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Table 1: Guidelines on target levels of markers of iron status in people with CKD.
Guidelines Continent Ferritin (𝜇g/l) TSAT (%)
Canadian Renal Guidelines Canada 100–500 >20
KDIGO Worldwide 100–500 >20
ERA-EDTA Europe 200–300 30–50
CARI Australia & New Zealand 200–500 30–40
KDOQI United States 200–500 30–50
UK Renal Association/NICE United Kingdom 250–500 >20
CARI: Caring for Australasians with Renal Insufficiency, KDOQI: Kidney Disease Outcome Quality Initiative, UK Renal Association: United Kingdom Renal
Association, NICE: National Institute forHealth andCare Excellence, ERA-EDTA: European Renal Association-EuropeanDialysis and Transplant Association,
and KDIGO: Kidney Disease: Improving Global Outcomes [1, 7].
that TSAT is a better marker of iron status than ferritin and
is more predictive of the response to treatment of anaemia
in MHD patients [6]. Therapeutic supplementation of iron
is provided to MHD patients until predetermined targets
of these measures are achieved. Internationally, the target
levels vary (Table 1). In our analysis, we used the ferritin and
TSAT target levels in the Kidney Disease: Improving Global
Outcomes (KDIGO) and Caring for Australasians with Renal
Insufficiency (CARI) guidelines and their modifications to
suit our local needs developed using the results from the
DRIVE studies because these guidelines encompass interna-
tional consensus and apply to our region, respectively.
We recently reported excessive serum ferritin concen-
trations among Indigenous Australian patients on MHD
[7]. However, anaemia management guidelines worldwide
presently do not guide iron supplementation in settings of
high ferritin, including when high ferritin, an acute phase
reactant, occurs in the setting of inflammation. The use of
either measure alone has significant problems with lack of
accuracy and has been discouraged in a recent special report
from the United Kingdom National Institute for Health and
Care Excellence (NICE) [8]. There is accumulating evidence
that high serum ferritin concentrations are associated with
high rates of hospitalisations, cardiovascular disease, and
mortality. Given the concerns of high dose iron supplemen-
tation in ESKD among populations with high background
serum ferritin levels and high comorbid cardiovascular dis-
ease, in this study, we examined the relationship between
serum ferritin levels and TSAT as measures of iron status
and serum ferritin levels and C-reactive protein (CRP)
as markers of inflammation among Indigenous Australian
patients dependent on MHD [7]. The analysis tested the
hypothesis that (1) the high serum ferritin levels and TSAT
may be inadequate as measures of iron status and (2) the
high serum ferritin levels had no association with CRP as an
inflammatorymarker in Indigenous Australian patients from
the Northern Territory who were on MHD.
2. Materials and Methods
2.1. Study Design and Participant Selection. We performed a
retrospective cohort analysis of prospectively collected data
for the 8-year period from 2004 to 2011 from the renal units
serving a majority of Indigenous Australian population of
Northern Australia. Adult patients over 18 years of age who
had been onmaintenance haemodialysis for at least 3 months
were included in the analysis.
2.2. Data Source and Selection. Deidentified data were
extracted from the Renal Anaemia Management (RAM)
database which contained data collected prospectively every
month from all renal units. The RAM database is a system
developed by ©Syreon Corporation: Vancouver, BC, Canada,
and was maintained by Janssen-Cilag© Pty Limited from all
the renal units.
The data from the RAM database was imported into
Stata for exploration for errors and consistence. Data quality
checks for data integrity was performed that no significant
information was lost during the transfer. Only variables
relevant to the aims of the analysis were included in the final
dataset.
2.3. Statistical Analysis. Exploratory analysis was performed
for each variable summarising the data as means and their
standard deviations (SD) for continuous normally distributed
variables and medians and interquartile ranges (IR) for
variables with skewed distributions. A summary analysis
was also performed by ethnicity. Pearson’s product-moment
correlation was run to assess the relationship between (1)
ferritin and TSAT as measures of iron status and (2) ferritin
and CRP as markers of inflammation.
As part of building a statistical model to assess the
relationship between ferritin and TSAT and CRP, a bivariate
analysis of the relationship between ferritin and each of the
variables was first performed. As the data was longitudinal
with multiple observations for each variable and some of
them unequally balanced, analyses were carried out using
mixed models approach including a random intercept and
a random effect to take account of intercorrelation between
measurements taken over time for the same patient. Associ-
ations of ferritin with the variables were therefore assessed
by (1) mixed regression analysis with ferritin as a continuous
dependent variable and TSAT as the primary predictor
variable and the rest of the variables as covariates and (2)
mixedmultinomial logistic regression analysis for categorical
data with ferritin as a categorical variable as outlined below.
For fitting a regression model to assess the association
between ferritin and TSAT with ferritin as a continuous
dependent variable, a square root transformation of the
ferritin levels was required as the distribution of ferritin was
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Table 2: Differences in variables by ethnicity.
Variable Whole sample Indigenous Non-Indigenous 𝑝 value (by ethnicity)
Ferritin (𝜇g/l) 1022 (590–1491) 1069.5 (668–1522) 558.5 (199–1252) <0.001
Transferrin saturation (%) 26 (19–37) 26 (19–37) 28 (20–38) 0.516
Haemoglobin (g/l) 107.6 (18.2) 106.6 (18.8) 113.2 (19.0) <0.001
Potassium (mmol/l) 4.66 (0.86) 4.7 (0.9) 4.6 (0.8) 0.398
BMI (kg/m2) 26.8 (5.9) 26.3 (6.0) 26.4 (5.2) 0.259
CRP (mg/l) 13.9 (6.0–33.1) 14.7 (7–35) 5.9 (1.9–17.5) <0.001
Corrected calcium (mmol/l) 2.27 (0.22) 2.26 (0.22) 2.32 (0.19) <0.001
Albumin (g/l) 37.8 (5.5) 37.7 (5.5) 38.6 (5.4) <0.001
Magnesium (mmol/l) 0.80 (0.14) 0.79 (0.13) 0.83 (0.16) <0.001
Bicarbonate (mmol/l) 23.7 (4.6) 23.6 (4.7) 24.0 (4.1) <0.001
Calcium phosphate product 3.67 (1.40) 3.66 (1.41) 3.75 (1.43) 0.163
Phosphate (mmol/l) 1.63 (0.65) 1.63 (0.65) 1.63 (0.63) 0.163
KT/V 1.61 (0.25) 1.61 (0.26) 1.61 (0.23) 0.171
URR (%) 74.6 (9.3) 74.8 (9.1) 73.2 (11.1) 0.010
ESA dose (IU per week) 11517 (8350) 11691 (8286) 9945 (8757) <0.001
Data are median (IR) or mean (SD) as indicated.
positively skewed. A variance component model was per-
formed to assess if there was sufficient variance represented at
a higher level in the data to justify the use of the mixedmodel
approach. The currently accepted rule is that at least 10% of
the total variance needs to be represented at a given level
[9]. We used the level of the RAMID (level 2) and the level
of the observations (level 1) to determine the total variance.
Using only ferritin with no predictors, an empty model
was created giving the variance component model estimates
at level 2 (i.e., RAMID) and at level 1 (i.e., observations).
Estimates from the variance components model were used to
calculate the Intraclass Correlation Coefficient (ICC) which
was determined as level 2 (RAMID) variance divided by level
2 (RAMID) variance + level 1 (observations) variance. The
ICC was 444.35772/(444.35772 + 521.78122) = 0.42037432.
This means that approximately 42% of the total variance in
the ferritin levels was represented at the level of the RAMID
which is well above the 10% expected to justify using the
mixed model. TSAT was then added to the model as the
primary predictor followed by the other covariates to build a
final multivariable model. Interaction between variables was
also assessed, particularly the interaction between ethnicity
and the other variables, using product terms to determine any
potential interaction among the predictor variables.
For the second part of the assessment ferritin was cate-
gorized into 4 categories as low (less than 100 𝜇g/l), “within
treated range” (100–800 𝜇g/l), high (800–1200𝜇g/l), and very
high (>1200 𝜇g/l) according to our local guidelines [7] to
assess if there were any associations between the different
categories of ferritin and TSAT, CRP, and the other variables.
TSAT was also categorized as low (<20%), “within treated
range” (≥20% to ≤30%), high (>30% to <50%), and very high
(≥50%) and CRP as low (<10mg/l) and high (≥10mg/l).
We also performed complementary sensitivity analyses
splitting the sample by ethnicity into Indigenous patients
versus non-Indigenous patients in order to examine the
association between ferritin andCRP and ferritin and infused
iron dose in participants where the infused dose of iron was
available.
All analyses were performed using Stata (R) version 13.1
(SE Copyright 1985–2013).
3. Results
There were 1568 adult patients in the study with a mean
age of 53.9 (11.9) years; 79.3% (𝑛 = 1244) were Indigenous
Australian patients; and 44.2% were male (𝑛 = 693).
Indigenous patients were younger than non-Indigenous [52.3
(11.1) years versus 57.4 (15.2) years, 𝑝 < 0.001]. The common-
est comorbidities in Indigenous patients were hypertension
(61.9%), diabetes mellitus (66.6%), and coronary artery dis-
ease (61.6%).
Compared with non-Indigenous patients, Indigenous
Australian patients had lower haemoglobin (𝑝 < 0.001),
higher serum ferritin levels (𝑝 < 0.001), CRP (𝑝 < 0.001),
URR (𝑝 = 0.010), and ESA weekly dose (𝑝 < 0.001). There
were no differences for phosphate (𝑝 = 0.163), calcium and
phosphate product (𝑝 = 0.173), BMI (𝑝 = 0.259), TSAT
(𝑝 = 0.516), and KT/V (𝑝 = 0.171) (Table 2).
3.1. Correlation between Ferritin and TSAT, CRP, and Other
Covariates. Ferritin was positively correlated with TSAT
(𝑟2 = 0.11, 𝑝 < 0.001) and had a significant association
with URR (𝑝 < 0.001) and KT/V (𝑝 = 0.024). Ferritin
was inversely associated with non-Indigenous ethnicity com-
pared to Indigenous (𝑝 < 0.001), older age (𝑝 < 0.001), and
higher BMI (𝑝 = 0.009). There was no correlation observed
between ferritin and CRP (𝑟2 = 0.001, 𝑝 < 0.001) (Table 3
and Figures 1 and 2).
3.2. Mixed Regression Model of Serum Ferritin with TSAT
as Predictor Variable. A final model developed by stepwise
4 International Journal of Nephrology
Table 3: Bivariate association of ferritin and other factors using mixed methods.
Variable Coefficient 𝑝 value 95% confidence interval
Male∗ 0.05 0.590 −0.36–1.12
Non-Indigenous∗∗ −50.70 <0.001 −65.60–−37.95
Haemoglobin 0.00 0.069 0.00–0.00
Potassium 0.10 0.115 −0.03–0.23
Albumin 0.00 0.981 −0.02–0.02
Corrected calcium −0.09 0.768 −0.69–0.51
Phosphate 0.17 0.085 −0.02–0.37
Calcium phosphate product 0.09 0.068 −0.01–0.18
Parathyroid hormone 0.001 0.800 −0.01–0.01
CRP 0.001 0.546 −0.001–0.003
Urea reduction ratio 0.06 <0.001 0.03–0.09
KTV 2.38 0.024 0.31–4.46
Age at the last review date −0.06 <0.001 −0.09–−0.03
Body mass index −0.08 0.009 −0.14–−0.02
Weekly darbepoetin dose 0.00 0.989 −0.01–0.01
Weekly epoetin alfa dose 0.00 0.891 0.00–0.00
∗Female is the baseline. ∗∗Indigenous is the baseline.
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Figure 1: Scatter plot of the relationship between serum ferritin
concentration and TSAT.
sequential selection and addition of variables with a signif-
icance level of 𝑝 < 0.25 from the bivariate analysis inclu-
ded no interaction terms as there was no significant inter-
action between the different covariates. After adjusting for
all the covariates, there remained a statistically significant
association between ferritin and TSAT (𝑝 < 0.001), ethnicity
(𝑝 < 0.001), and URR (𝑝 = 0.001) (Table 4). There was no
significant association with CRP.
On mixed multinomial logistic regression, categories of
ferritin were positively associated with “within treated range”
and higher categories of TSAT (𝑝 < 0.001), Indigenous
ethnicity (𝑝 < 0.001), and male gender (𝑝 < 0.001). There
was no association between ferritin categories and all CRP
categories (Table 5).
Ferritin
Fitted values
Scatter plot of the relationship between ferritin and C-reactive protein
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Figure 2: Scatter plot of the relationship between serum ferritin
concentration and CRP.
We found that although ferritin levels and CRP were
higher in Indigenous Australian patients, the sensitivity anal-
yses of the examination of the association between ferritin
and CRP and ferritin and infused iron dose in participants
where the infused dose of iron was available did not alter the
findings observed in the combined cohort.
4. Discussion
Indigenous MHD patients in this study had lower haemo-
globin, higher ferritin, CRP, and ESA weekly dose, despite
similar concentration of TSAT and similar degree of mea-
sures of dialysis adequacy than non-Indigenous patients. Two
key findings in this analysis were as follows: (1) the high
ferritin levels in our patients are only partly explained by iron
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Table 4: The final model after stepwise sequential fitting of the model.
Variable Change in square root of ferritin level∗ 𝑝 value 95% confidence intervals
TSAT (%) 0.04 <0.001 0.04–0.05
Indigenous (1.00) — —
Non-Indigenous −13.47 <0.001 −29.16–3.80
URR 0.04 0.001 0.02–0.07
∗Change in the square root of ferritin per unit change in the independent variables.
Table 5: Results of two-level (multilevel) multinomial logistic regression: final model.
Predictor Ferritin (𝜇g/l) categories
∗
Category 2 ≥ 100 < 800 Category 3 ≥ 800 < 1200 Category 4 ≥ 1200
TSAT ≥ 20% and ≤30%
1.58 2.31 2.35
<0.001 <0.001 <0.001
1.39–1.77 2.12–2.51 2.15–2.54
TSAT > 30% and ≥50%
2.28 3.33 3.67
<0.001 <0.001 <0.001
1.98–2.57 3.03–3.63 3.37–3.96
TSAT > 50%
2.67 4.15 4.99
<0.001 <0.001 <0.001
2.02–3.32 3.50–4.80 4.34–5.64
Non-Indigenous ethnicity
−2.46 −3.43 −3.53
<0.001 <0.001 <0.001
−2.88–−2.04 −3.85–−3.00 −3.96–−3.11
Male gender
1.49 1.33 1.19
<0.001 <0.001 <0.001
1.13–1.86 0.96–1.70 0.82–1.56
CRP ≥ 10mg/l
−0.04 −0.07 −0.09
0.693 0.513 0.375
−0.24–0.16 −0.28–0.14 −0.30–0.11
Data are coefficient, 𝑝 value, and 95% confidence interval. Reference groups for categorical variables are TSAT < 20%, female gender, Indigenous ethnicity,
and CRP < 10mg. ∗Compared to base outcome of ferritin category 1 (serum ferritin < 100𝜇g/l).
levels (TSAT) and (2) high ferritin levels in our patients are
likely to be poorly explained by inflammation given the poor
association between ferritin and CRP.
Recent evidence has shown that TSAT (compared with
serum ferritin) was a better predictor of iron status and
response to treatment with ESA in dialysis patients [6].
Our data revealed that only 11% of the variation in ferritin
levels could be explained by the TSAT with 89% bearing
no relationship. Although there was a statistically significant
association between ferritin and TSAT on mixed regression
analysis, a unit rise in TSAT was associated with a very
small rise in ferritin which supports the correlation findings.
This suggests that the high ferritin levels in our patients
are only partly explained by iron levels. Our local iron
management protocols have focussed on serum measures of
TSAT and ferritin and are thus in accordance with other
international anaemia management guidelines (Table 1). Yet
we have shown that TSAT and ferritin are in fact likely
to insufficiently direct optimal iron replacement, given the
lower achieved haemoglobin among Indigenous clients in
this cohort. Consequently, there is a clear need to explore
other measures of iron status in addition to the ferritin and
TSAT.
We recently reported that our patients, who have high
serum ferritin concentrations, are also exposed to higher than
usual levels of therapeutic iron doses [7], which is one conse-
quence of a persisting evidence gap to guide management of
iron deficiency in dialysis patients with high ferritin. In our
patients, high serum ferritin concentrations, in combination
with low TSAT, are observed prior to haemodialysis initia-
tion. In contrast, data from the United States has shown that,
with reductions in ESA use and increased iron supplemen-
tation, a rise in serum ferritin concentration among MHD
patients is observed [10]. In the mixed regression analysis, we
also showed no association between ferritin and ESA weekly
dose, even though Indigenous patients required significantly
higher doses of ESA.
We investigated the effect of inflammation, using CRP,
as an alternate differential of high serum ferritin. Dialysis
patients are known to have high vulnerability to bacterial
infections [11], in our region, melioidosis bacteraemia [12],
and staphylococcal bacteraemia [13]. In spite of this, our
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data showed that CRP was not associated with serum ferritin
levels in maintenance haemodialysis patients. This suggests
as yet unexplained causes of high serum ferritin, beyond
infection in this population. This data was reported from a
retrospective clinical dialysis database. Therefore, we did not
have other more specific or novel measures of inflamma-
tion. We acknowledge that other markers of infectious and
noninfectious inflammation may have been better surrogates
of relationship between ferritin and inflammation. These
may include more specific inflammatory markers such as
interleukin-6 (IL-6) and tumour necrosis factor-a (TNF-a)
[14].
Although the possibility of iron overload as a potential
explanation for the lack of association between the high
ferritin and CRP was considered, an analysis of the available
data supported what we found in our other recent study that
the administered iron did not explain the lack of association
between the high ferritin and the CRP [7].
Although we performed sensitivity analyses which
showed no difference in the association between ferritin
and CRP and ferritin and infused iron dose in participants
where the infused dose of iron was available compared to
the findings observed in the combined cohort, the lack
of association between ferritin and infused iron dose and
ferritin and CRP may be explained by the low data for
infused iron dose available in the dataset.
There is a significant potential risk of iatrogenic iron over-
load generated by the administration of iron in our dialysis
patients with high ferritin where guidelines are lacking on
the appropriate dosing in those with other evidence of iron
deficiency. Although we have adjusted our local guidelines
[7] in line with the findings in the Ferric Gluconate Is Highly
Efficacious in Anaemic Haemodialysis Patients with High
Serum Ferritin and Low Transferrin Saturation: Results of
the Dialysis Patients’ Response to IV Iron with Elevated
Ferritin (DRIVE) studies [15, 16], a significant number of
patients have the high ferritin levels above those used in these
studies. Therefore, this needs further evaluation. A cross-
sectional study assessing the best markers of iron stores in
this population will be informative in helping to determine
the best measures of the iron stores. However, the appropriate
dosing of iron will need to be evaluated by a clinical trial
comparing outcomes between the dosing of iron among
different levels of high ferritin.
Dialysis adequacy as measured by URR was highly
significantly associated with higher ferritin. This may reflect
either better utilisation of iron in those patients who are
dialysing well compared to those with poor dialysis or an
indication that those who attend adequate dialysis receive
iron treatment. This will need further assessment, including
a prospective study as the question was beyond the scope of
this study.
The lack of correlation with ferritin and TSAT suggests
the need to examine the role of regulatory and functional
markers of iron such as hepcidin [17–21] and other measures
of iron stores, particularly soluble transferrin receptor which
has been shown to be a better marker of iron status than
ferritin in Indigenous children [22]. Other measures of
iron stores such as low MCV and hypochromic, microcytic
RBCs on blood film, percentage hypochromic red cells
(PHRC), and reticulocyte haemoglobin content will need
further exploration in prospective studies in this population.
Although the PHRC produces comparable or somewhat
better results than reticulocyte haemoglobin content, the
blood sample needs to be analyzed on site, which makes its
widespread adoption difficult in our setting [23].
Causes of very high serum ferritin concentrations
(>10,000 𝜇g/l) include genetic causes, transfusional iron over-
load, juvenile idiopathic arthritis, lupus, and haemophago-
cytic lymphohistiocytosis. Iron overload may be another
differential of high serum ferritin in this cohort, although
our data did not support this among our patients, since the
TSATwas not elevated. Direct assessments of iron status such
as measuring liver iron levels could be considered [24]. The
traditional invasive methods to determine body iron levels
such as bone marrow biopsy [25] and liver biopsy are associ-
ated with increased mortality and morbidity [26]. However,
the recent increase in the use of noninvasive but accurate
methods such as the magnetic resonance imaging- (MRI-)
based technique spin-density projection-assisted (SDPA) R2-
MRI (FerriScan) provides an opportunity to determine the
relationship between the high ferritin and liver iron status to
exclude iron overload [27–29].
Almost 20 years ago,Moirand et al. identified the relation-
ship between unexplained high serum ferritin (median values
> 500 𝜇g/l) and normal transferrin saturation [30]. They
reported that the majority of participants with unexplained
high serum ferritin had numerous clinical indicators of the
metabolic syndrome [30]. This has also been supported
more recently [31], with ferritin having strong association
with insulin and c-peptide, which unfortunately were not
routinely available in all our patients. It is reported that
insulin increases externalisation of the transferrin receptor,
thereby stimulating cellular iron uptake. Type 2 diabetes is
a leading cause of end stage kidney disease in Indigenous
Australians [32] and reflected in 66.6% of our participants.
Hyperinsulinaemia and metabolic syndrome are also highly
prevalent among the general population of Indigenous Aus-
tralians in our region [33, 34]; hyperferritinaemia in the
absence of acute infection may potentially reflect sustained
hyperinsulinaemia among our patients. We therefore plan to
investigate the association between high serum ferritin and
markers of the metabolic syndrome in our MHD patients.
The study had several limitations including the retrospec-
tive design which is associated with potential bias due to
reliance on data collected for a different aim to the study.
However, there was enough information in the datasets to
confidently assess the relationship between ferritin and the
other variables to answer the question. Some important infor-
mation on essential variables to this analysis was incomplete;
for example, total dose of iron per annum had too few
observations in the first few years of the data collection
to be included in the analysis. This may have affected the
levels of ferritin. However, this would not have affected the
relationship between ferritin and TSAT as both are expected
to rise with iron therapy. One of the limitations of the study
as a retrospective analysis was that the data collection for iron
infusion was not complete. In the earlier years covered by the
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study, the data entry was limited to whether iron infusionwas
given or notwithout specifying the dose. It was only in the last
12months that the dose was included in the entry.Most of the
analysis was performed on the whole sample and then by eth-
nicity. However, detail could not be provided on iron infusion
and ferritin by ethnicity due to the limited available data.
A prospective study is also required to further compre-
hensively explore the potential causes of the high ferritin and
the clinical outcomes that may be associated with the high
ferritin in this patient group. Future studies to clarify these
unanswered questions include a prospective study which
combines assessing the association of ferritin with measures
of regulatory and functional markers of iron status such as
hepcidin, markers of inflammation mentioned above, and
other surrogate methods of assessing iron status such as
soluble transferrin receptor will provide a clear method of
assessing iron status in our patients. Hepcidin is particularly
increasingly recognised as a key player in iron metabolism
and will need exploration in this population especially with
respect to functional iron deficiency [17, 35]. An assess-
ment of the relationship between ferritin and other clinical
correlates such as hepatitis B infections, hospitalisations,
cardiovascular disease, other infections, and conditions such
as diabetes mellitus will also need further studies.
The implication of this study is that it raises questions
on the veracity of using ferritin and transferrin saturation
as the main determination of iron requirements and therapy
in Indigenous patients on haemodialysis. The study clearly
raises the need to further explore the use of other measures
of iron stores. It also raises the need to conduct a clinical
trial assessing the safety and efficacy of administering iron in
patients with higher ferritin levels than in the DRIVE studies
[15, 16].
5. Conclusion
We report a population of MHD clients with high ESA
usage, hyperferritinaemia, and low-normal TSAT. Our data
has revealed the limited utility of using only ferritin and
TSAT to guide Renal Anaemia Management protocols in our
region.We suggest exploring the utility of additional markers
of iron status to guide our clinical practice. We have further
shown the lack of correlation of ferritin with serum CRP,
as a marker inflammation. There is clear need for further
evaluation of the causes of this high ferritin and the possible
associated detrimental clinical outcomes in these patients.
Unlike populations without severe renal disease, we suspect
that there may be an association between hyperferritinaemia
and metabolic syndrome which could explain some of the
variance in high serum ferritin concentrations in our patients.
Should this be confirmed in future studies in our patients,
then interventions targetingmetabolic syndromemay also be
incorporated into our local anaemia management guidelines.
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